Stockholm, Sweden – March 23, 2010 – Swedish Orphan Biovitrum (STO: BVT) has submitted new data to the Committee for Medicinal Products for Human Use (CHMP), which adopted a positive opinion recommending a variation to the terms of the marketing authorisation for Kepivance®. The new label with an updated SmPC will be implemented after the European Commission has approved the CHMP recommendation.

Please read the whole press release here.